Literature DB >> 24646741

IFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection.

Ichiro Misumi1, Jason K Whitmire.   

Abstract

IFN-λ induces an antiviral state in many cell types and may contribute to the overall inflammatory environment after infection. Either of these effects may influence adaptive immune responses, but the role of type 3 IFNs in the development of primary and memory T cell responses to infection has not been evaluated. In this study, we examined T cell responses to acute or persistent lymphocytic choriomeningitis virus infection in IFN-λR1-deficient mice. Following acute infection, we find that IFN-λR1-deficient mice produced normal levels of IFN, robust NK cell responses, but greater than normal CD4+ and CD8+ T cell responses compared with wild type BALB/c mice. There were more T cells that were IL-7R(hi) and, correspondingly, the IFN-λR-deficient mice showed a 2- to 3-fold increase in memory T cell number. The inhibitory effect of IFN-λR expression was independent of direct cytokine signaling into T cells. In contrast with acute infection, the IFN-λR-deficient mice generated markedly diminished T cell responses and had greater weight loss compared with wild type mice when confronted with a highly disseminating variant of lymphocytic choriomeningitis virus. These data indicate that IFN-λR limits T cell responses and memory after transient infection but augments T cell responses during persisting infection. Thus, the immune-regulatory functions for IFN-λR are complex and vary with the overall inflammatory environment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24646741      PMCID: PMC4157331          DOI: 10.4049/jimmunol.1301705

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  118 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity.

Authors:  Philipp A Lang; Karl S Lang; Haifeng C Xu; Melanie Grusdat; Ian A Parish; Mike Recher; Alisha R Elford; Salim Dhanji; Namir Shaabani; Charles W Tran; Dilan Dissanayake; Ramtin Rahbar; Magar Ghazarian; Anne Brüstle; Jason Fine; Peter Chen; Casey T Weaver; Christoph Klose; Andreas Diefenbach; Dieter Häussinger; James R Carlyle; Susan M Kaech; Tak W Mak; Pamela S Ohashi
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-13       Impact factor: 11.205

3.  IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion.

Authors:  Warren N D'Souza; Leo Lefrançois
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

4.  Interferon-λ mediates oral tolerance and inhibits antigen-specific, T-helper 2 cell-mediated inflammation in mouse intestine.

Authors:  Shao-Heng He; Xiao Chen; Chun-Hua Song; Zhi-Qiang Liu; Lin-Fu Zhou; Wen-Jing Ma; Lei-Di Zhao; Tong-Li Li; Shang-Guo Tang; Zhou Xing; Ping-Chang Yang
Journal:  Gastroenterology       Date:  2011-04-16       Impact factor: 22.682

5.  Induction of interferon-γ contributes to Toll-like receptor 3-mediated herpes simplex virus type 1 inhibition in astrocytes.

Authors:  Jieliang Li; Li Ye; Xu Wang; Shuxian Hu; Wenzhe Ho
Journal:  J Neurosci Res       Date:  2011-11-04       Impact factor: 4.164

6.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.

Authors:  Andrew J Muir; Mitchell L Shiffman; Atif Zaman; Boris Yoffe; Andrew de la Torre; Steven Flamm; Stuart C Gordon; Paul Marotta; John M Vierling; Juan Carlos Lopez-Talavera; Kelly Byrnes-Blake; David Fontana; Jeremy Freeman; Todd Gray; Diana Hausman; Naomi N Hunder; Eric Lawitz
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

7.  Viral targeting of fibroblastic reticular cells contributes to immunosuppression and persistence during chronic infection.

Authors:  Scott N Mueller; Mehrdad Matloubian; Daniel M Clemens; Arlene H Sharpe; Gordon J Freeman; Shivaprakash Gangappa; Christian P Larsen; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-18       Impact factor: 11.205

8.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

9.  Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells.

Authors:  Seung-Ho Hong; Okki Cho; Koyngmin Kim; Ho-Joon Shin; Sergei V Kotenko; Sun Park
Journal:  Virus Res       Date:  2007-04-23       Impact factor: 3.303

10.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells.

Authors:  Matthew A Williams; Aaron J Tyznik; Michael J Bevan
Journal:  Nature       Date:  2006-06-15       Impact factor: 49.962

View more
  18 in total

Review 1.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 2.  Shared and Distinct Functions of Type I and Type III Interferons.

Authors:  Helen M Lazear; John W Schoggins; Michael S Diamond
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

3.  Targeting IFN-λ Signaling Promotes Recovery from Central Nervous System Autoimmunity.

Authors:  Sindhu Manivasagam; Jessica L Williams; Lauren L Vollmer; Bryan Bollman; Juliet M Bartleson; Shenjian Ai; Gregory F Wu; Robyn S Klein
Journal:  J Immunol       Date:  2022-02-18       Impact factor: 5.426

4.  The innate immune receptor MDA5 limits rotavirus infection but promotes cell death and pancreatic inflammation.

Authors:  Yu Dou; Howard Ch Yim; Carl D Kirkwood; Bryan Rg Williams; Anthony J Sadler
Journal:  EMBO J       Date:  2017-08-29       Impact factor: 11.598

Review 5.  Interferon-λ orchestrates innate and adaptive mucosal immune responses.

Authors:  Liang Ye; Daniel Schnepf; Peter Staeheli
Journal:  Nat Rev Immunol       Date:  2019-06-14       Impact factor: 53.106

Review 6.  Interferon-λ: Immune Functions at Barrier Surfaces and Beyond.

Authors:  Helen M Lazear; Timothy J Nice; Michael S Diamond
Journal:  Immunity       Date:  2015-07-21       Impact factor: 31.745

Review 7.  Interferon Lambda Genetics and Biology in Regulation of Viral Control.

Authors:  Emily A Hemann; Michael Gale; Ram Savan
Journal:  Front Immunol       Date:  2017-12-06       Impact factor: 7.561

8.  Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.

Authors:  Florian Douam; Yentli E Soto Albrecht; Gabriela Hrebikova; Evita Sadimin; Christian Davidson; Sergei V Kotenko; Alexander Ploss
Journal:  mBio       Date:  2017-08-15       Impact factor: 7.867

Review 9.  Interferon Lambda: Modulating Immunity in Infectious Diseases.

Authors:  Mohammedyaseen Syedbasha; Adrian Egli
Journal:  Front Immunol       Date:  2017-02-28       Impact factor: 7.561

10.  Interferon lambda is required for interferon gamma-expressing NK cell responses but does not afford antiviral protection during acute and persistent murine cytomegalovirus infection.

Authors:  Silvia Gimeno Brias; Morgan Marsden; Jessica Forbester; Mathew Clement; Cordelia Brandt; Katherine Harcourt; Leanne Kane; Lucy Chapman; Simon Clare; Ian R Humphreys
Journal:  PLoS One       Date:  2018-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.